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Abstract 
 
The analysis and planning methods for competing risks model have been described in the literatures 
in recent decades, and non-inferiority clinical trials are helpful in current pharmaceutical practice. 
Analytical methods for non-inferiority clinical trials in the presence of competing risks were 
investigated by Parpia et al., who indicated that the proportional sub-distribution hazard model is 
appropriate in the context of biological studies. However, the analytical methods of competing risks 
model differ from those appropriate for analyzing non-inferiority clinical trials with a single 
outcome; thus, a corresponding method for planning such trials is necessary. A sample size formula 
for non-inferiority clinical trials in the presence of competing risks based on the proportional 
sub-distribution hazard model is presented in this paper. The primary endpoint relies on the 
sub-distribution hazard ratio. A total of 120 simulations and an example based on a randomized 
controlled trial verified the empirical performance of the presented formula. The results demonstrate 
that the empirical power of sample size formulas based on the Weibull distribution for 
non-inferiority clinical trials with competing risks can reach the targeted power. 
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1. Background 
Anderson et al. (2012) described the concept of generalized survival analysis, 
which mainly refers to multi-state model, of which single-event survival analysis and 
the competing risks model are special cases. Single-event survival analysis is used to 
analyze survival data in which an event can only occur once for each patient. In a 
competing risks framework, more than one type of event can occur to the patients under 
follow-up, and all of the events are absorbing (absorbing state). The competing event 
prevents the event of interest from occurring. Numerous studies have focused on 
methods for the inference and modeling of competing risks data in recent decades, but 
few designed studies that are based on a competing risks framework have been 
performed (Pintilie, 2002; Schulgen, 2005; Maki, 2006; Latouche, 2004; Latouche, 
2007; Tai, 2015).  
Sample size determination is an important aspect of clinical trial planning and 
design. Sample size formulas have been published for trials in the presence of 
competing risks (Pintilie, 2002; Schulgen, 2005; Maki, 2006; Latouche, 2004; Latouche, 
2007; Tai, 2015), and the null hypothesis in all of these trials is no difference between 
two treatments, which is termed superiority testing. Some sample size formulas are 
developed based on the cause-specific hazard (CSH) ratio (Pintilie, 2002; Schulgen, 
2005; Maki, 2006), whereas others use the sub-distribution hazard (SDH) ratio 
(Latouche, 2004; Latouche, 2007).  
However, non-inferiority designs are necessary in some cases because similarity to 
an existing effective therapy can justify a product being on the market and providing 
more treatment options for patients. When competing risks are present, proportional 
sub-distribution hazards, Cox proportional hazards and marginal models can be used for 
descriptive purposes and inference. Parpia et al. (2013) discussed the performance of 
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these methods in non-inferiority clinical trials in the presence of competing risks 
(NiCTCR) and indicated that aside from biological studies, the sub-distribution hazard 
model is preferred because of its advantage of intuitive explanation. Although 
non-inferiority method in clinical trials in the presence of competing risks is as 
necessary as method in clinical trials with single-event survival analysis, the lack of an 
applicable sample size determination method for planning NiCTCR has limited its 
development. Therefore, we present a sample size formula for NiCTCR in this paper. 
The article is organized as follows. In Section 2, background information on 
competing risks and associated modeling methods of competing risks are introduced. A 
sample size formula for NiCTCR with the Weibull survival time assumption is 
presented. A numerical simulation is conducted to verify the usefulness of the sample 
size formula in non-inferiority clinical trials in the presence of competing risks in 
Section 3, and the results from the simulation are presented. The presented formula for 
NiCTCR is illustrated with an example in Section 4. Section 5 discusses various 
considerations of parameter settings and potential arguments. Detailed technical 
derivations are provided in the Appendix. 
 
2. Methods 
Basic quantities of the competing risks model 
More than one type of event can occur during the follow-up period in the 
framework of the competing risks model. In this paper, two events are considered 
without a loss of generality. The primary endpoint is the time to some negative event of 
interest, whereas a separate event is regarded as the competing event. The negative 
event of interest, for example, cancer death or progression of cancer, indicates that a 
high hazard rate corresponds to unsatisfactory efficacy. The occurrence of the 
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competing event may affect the event of interest. Some basic descriptive statistics and 
models for the framework of competing risks are provided in this section. 
Let iT  be the recorded time to failure of the ith subject, where i =1,…,N. N 
denotes the total sample size. D implies the state code, which is the event of interest (D 
= 1), competing event (D = 2) or censoring (D = 0). id  denotes the state code of the ith 
subject. 
The CSH function for the abovementioned event of interest is expressed as 
follows: 
0
( , 1 | )l( im)C
t
S P t T t t D T tth
t 
       . 
The risk set of CSH includes subjects who are still under follow-up and who have not 
experienced any event, i.e., ( ) { | , 1, , }i
CSRS t i T t i N    . 
The other basic descriptive statistic, the cumulative incidence function (CIF), is a 
measure of the actual probability of events because it considers the competing cause 
when estimating the incidence rate for the event of interest. The CIF for the event of 
interest is defined as 
0
( ) ( ) ( ) ( )
t CSF t P T t S u h u du    , where S(t) is the event-free 
survival function. By derivation, ( ) ( 1)F P D    can be obtained. Therefore, the CIF 
is not an appropriate probability distribution. The CIF derivative ( )( ) F tf t
t
   is defined 
as the sub-density function. 
Using the CIF as the basis for construction, the SDH for the event of interest is 
defined as follows: 
0
{ , 1 | ( 1)}( ) limD
t
S P t T t t D T t T tt
t
h D 
           . 
The risk set of the SDH model is as follows: 
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( ) { | ( 1), 1, , }i i
SD
iRS t i T t T t d i N        . 
A semi-parametric proportional hazards model for the SDH of the failure times of 
interest (Fine, 1999) is constructed as follows: 
 0( | ) ( ) exp( )
SDSD t xh h t bx ,  (1) 
where 0 ( )
SDh t  is the baseline sub-distribution hazard for the event of interest, and x and 
b denote the covariate and its coefficient, respectively. 
Based on the definition of CSH, the sample size formula for comparing the CSHs 
in non-inferiority clinical trials is the same as that for comparing hazards in the Cox 
proportional hazard model (Formula (3) with 1 1   and a truncated exponential 
enrollment distribution in Crisp et al. (2008)), as follows: 
 
2
/2
2
0 0 1
( )
[ln( )]x
CS
xCS CS
Z Z
N p
p p E
   , x = 0, 1, (2) 
where CSxN  is the sample size required for group x, CSE  is the probability of the event 
of interest that occurs in the entire study period after regarding the competing event as 
censoring, and 0
CS  is the non-inferiority margin of CSH. Type I and type II errors are 
denoted by   and  , respectively. Z  denotes the (1 ) -quartile of the standard 
Gaussian distribution, and 0p  and 1p  indicate the sample size percentage of groups 0 
and 1, respectively. 
Based on the abovementioned definitions and previous studies on the competing 
risks model (Lau, 2009; Putter, 2007), the CSH censors the competing events, but such 
censoring is assumed to be non-informative because the censoring time is assumed to be 
independent of the event time. However, the SDH treats the competing event as the 
event of interest with infinite event time. As a result, an individual with a competing 
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event remains in the risk set (Tai, 2011). The SDH is a measure of association that 
reflects both the association of the treatment with the event of interest and the 
contribution of a competing event by actively maintaining individuals in the risk set. 
Thus, the use of the proportional sub-distribution hazard model depicts the rules of a 
certain event more reasonably. Therefore, the sample size formula for NiCTCR 
presented in this study is based on the proportional sub-distribution hazard model and 
its statistics. 
 
Sample size formula for NiCTCR 
The hypotheses for non-inferiority clinical trials in the presence of competing risks 
are as follows: 
 0 0:H     vs. 1 0:H    ; (3) 
i.e., 0 0: lnH b    vs. 01 : lnH b   , 
where Δ(= exp( )b ) is the sub-distribution hazard ratio of the event of interest. 
0 ( 0exp( )b ) and 1 ( 1exp( )b , 1 0   ) are the non-inferiority margin and SDH 
ratio under 1H , respectively. The Wald statistic of b = b0 is 0( )N b b , and the 
estimator of b is expressed as bˆ . 0( )N b b  is approximately normal with zero mean 
and variance ( )V b , which is derived as the reciprocal of the information (Formula A.4 
in the Appendix). The partial likelihood of the model (1) can be constructed as follows: 
{ 1}
1
( )
exp( )( )
exp( )
i
SD
i
I d
N
i
i j
j RS T
bxL b
bx



      
  , 
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where I{CONDITION} is the indicator function, which returns to 1 when the 
CONDITION in the braces is true; otherwise, this function returns to 0. Similar to the 
assignment in Latouche et al. (2004), 0ix   and 1ix   indicate that the ith subject is 
assigned to the control and experimental groups, respectively. The information is 
expressed as follows: 
0 10
( ) ( ) ( ) ( )nI b t t U t dt   , 
where  
1
0
(1 ( ))(1 ( ))( )
[ (1 ( ))(1 ( ))] ( )
x x x
x
x x x
x
N F t F tt
N F t F t exp bx


 
  , x = 0, 1, and 
1
0
( ) ( )(1 ( ))xx
x
xU t p f t F t

  . 
xF  is the cumulative incidence function of the censoring and is assumed to be identical 
in the two groups, and ( )xf t  is the sub-density function in group x. The subscript x 
indicates the corresponding statistics in group x. The ( ) /x x xt N N p    is under the 
assumption 1 1  ; therefore, the following formula is obtained: 
 0 1 0( ) ( )nI b p p U t dt
  .  (4) 
Finally, the sample size formula can be derived as follows: 
 
2
1 /2
2
0 1 0 1
( ) #
[ln( ln( ]) )
Z Z EN
p p w w
      , (5) 
where 
0
( )w U t dt
   implies the incidence rate of both groups, and #E implies the 
calculated events needed in two groups. 
We assume that the survival time of the event of interest in both groups is Weibull 
distributed. The scale parameter of the event of interest in group x is 1x , and the shape 
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parameter denoted by 1k  is assumed to be identical in both groups. The survival time 
of the competing cause in both groups is assumed to be the same and Weibull 
distributed, with the respective scale and shape parameters of 2  and 2k .   is the 
identical hazard rate of the exponential censoring time in both groups. fT  and R denote 
the follow-up period and accrual time, respectively. 
1
0
x
x
w w

   can be calculated using 
the following formula: 
 1 111 1 1 10 exp( )exp( )  
    f
f
T R t k kx
x x xT
qw k u u u dudt
R
, x = 0, 1, (6) 
where 1xq  denotes the probability that an individual who has not experienced any 
event occurrence undergoes the event of interest given that individual undergoes any 
event; i.e., 
1
count of event of interest occuring in group 
count of any event occuring in group x
xq
x
 , x = 0, 1. 
Formula (6) can be derived from the sum of two single integrals as follows:  
 1
0
[ fun( ) ( )fun( ) ]f f
f
T T Rx
x fT
qw R u du T R u u du
R
     , x = 0, 1, (7) 
where  
 1 111 1 1fun( ) exp( ) exp( )
k k
x xu k u u u     . 
To plan a conservative trial, the hazard rate was based on the alternative hypothesis in 
Formula (3), which indicates that the cumulative incidence rates are identical in two 
groups, to ensure a predetermined power (Crisp, 2008). 
 
3. Simulations 
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To verify the performance of the sample size formula of NiCTCR, 10,000 
simulations of 120 parameter combinations (Table A1 in the supporting material) were 
conducted by using R software (V2.15.2, http://www.R-project.org). The time to failure 
from each cause was generated using the indirect method (Beyersmann, 2011). Fine and 
Gray assumed that the cumulative incidence function of the failure of interest and 
competing event in group x follow the following model: 
1 exp( )
01 01( , 1 | ) 1 {1 [1 exp( )]}
k bx
i iP T t d x q t       , i = 1,…,N, 
2exp( )
01 2( , 2 | ) (1 ) {1 exp[ exp( )]}
kbx
i iP T t d x q t bx      , i = 1,…,N. 
Consequently, ( | , 0)i i iP T t d D x   , i = 1,…,N, is a Weibull distribution with shape 
Dk  and scale 0D . The proportional sub-distribution hazard model (1) can be derived 
as follows: 
 
1
011
1
01
1
01 01 1
01
( | ) exp( )
1 (1 )
k
k
tk
t
SD q k t eh t x bx
q e


    . 
A uniformly distributed enrollment time ir  and an exponential censoring time ic  
are generated for each individual i. Thus, the observed time is the minimum of iT , ic  
and f iT R r  . 
The time to the event of interest in the control group—i.e., the baseline SDH 
rate—is Weibull distributed, which is conditional on the occurrence of the event of 
interest, with two levels of the scale parameter ( 01 1, 2  ) and three levels of the shape 
parameter ( 1 0.5,1and 2k  ). These shape parameters determine the decreasing, 
constant and increasing trends of the hazard curve. We assume that only one competing 
cause may occur and that its distribution is a Weibull distribution with scale 
( 2 0.15 and 0.5  ) and shape ( 2 0.5,1and 2k  ) that is identical in the two groups. 
Different shape parameters between the failure of interest and competing failure are also 
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considered as follows: 1 2( 0.5, 1.5 )k k   and 1 2( 1.5, 0.5)k k  . An exponential 
censoring time with 0.1 and no random censoring is considered. The detailed parameter 
settings are listed in Table 1 (and Table A1 in the supporting material). 
The Fine-Gray proportional sub-distribution hazard model is used for modeling 
and estimating the confidence interval of SDH. Non-inferiority may be concluded when 
the upper limit of the two-sided 95% confidence interval for the SDH ratio does not 
exceed 0 . Type I error and power are calculated under the presetting situation where 
  for generating data is equal to 0  and 1 , respectively. 
As shown in Figure 1 (and Table A1 in the supporting material), the incidence 
rates of the censoring and competing events were simulated from 70% to more than 
20%. The three wavebands in each subgraph represent 01 0.3,  0.5,  0.8q   in order. The 
dashed line represents the type I error, which is approximately 0.025 (range of 0.021 to 
0.028). With the data generated under the alternative hypothesis, all of the empirical 
powers were approximately equal to the predetermined power of 0.8 (range of 0.791 to 
0.813). Thus, the proposed sample size formula performed very well using the 
simulated data.  
 
4. Example for NiCTCR 
To illustrate the implications in terms of the sample size formulas for NiCTCR, we 
used the study of Schroder et al. (2009) as an example. In that study, a randomized 
controlled trial to evaluate the effect of early (EET, control group) versus delayed (DET, 
experimental group) endocrine treatment in patients with lymph node-positive prostate 
cancer was performed. The primary endpoint was overall survival from randomization 
to the day of death. The secondary endpoint was set as cancer death (CD) and 
non-cancer death (NCD). The Kaplan-Meier method and Cox proportional hazards 
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model were used for the estimation, and the confidence intervals of the hazard rate of 
CD and NCD were used to test the non-inferiority of DET to EET with a non-inferiority 
margin of 1.5. In total, 234 patients were recruited to achieve 85% power and were 
randomly assigned at 1:1 to the EET and DET groups. In the CD comparison, NCD was 
treated as the competing risk. 
The proposed formula was utilized for planning this trial. The required parameters 
were extracted from a figure (Fig. 4) in Schroder et al.’s paper (2009). The median CD 
time was 8.4 years for DET and 9.45 years for EET. The hazard rate was calculated as 
follows: 101 ln(0.5) / 9.45
k   . For low NCD, the competing cause hazard rate was 
derived from the survival time at a 90% survival rate, which was 5.1 years. The hazard 
rate for the competing risk was obtained as follows: 22 ln(0.9) / 5.1
k   . The accrual 
interval was 12 years (1986 to 1998), whereas the follow-up time was approximately 
7.5 years. The CD and NCD rates in DET were 67.1% and 23.9%, respectively. Thus, 
01q  was equal to 0.737. Forty-one of 234 patients were prematurely withdrawn. 
Therefore, we supposed that the censoring hazard rate would equal 0.020 in the 
exponential censoring distribution. The sample size calculated from the presented 
sample size formula of NiCTCR is shown in Table 2. Several scenarios for the three 
shape parameters, with and without random censoring, were considered. 
A total of 110 events per group was required for the presented formula to achieve 
85% power. When the survival time was exponentially distributed with and without 
censoring, 272 and 243 patients were required, respectively. If the hazard rate decreased, 
the required sample size was slightly larger than that of the constant hazard because of 
the smaller hazard rate, whereas 288 and 269 patients per group, with and without 
random censoring, respectively, were necessary to increase the hazard rate survival time. 
When we used the sample size formula, Formula (2), for a single event or CSH in 
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non-inferiority clinical trials (Crisp, 2008) instead of the proposed sample size formula, 
Formula (5), all of the sample sizes calculated were smaller than those calculated for the 
proportional SDH model. Single-event survival analysis overestimates the incidence 
proportion of the event of interest by treating the competing event as censoring. 
Consequently, in studies involving sub-distribution modeling, applying the sample size 
formula of single-event non-inferiority clinical trials may underestimate the sample size 
required and result in underpowered trials. 
 
5. Results and discussion 
In this paper, we derived a sample size formula based on the proportional 
sub-distribution hazard model using the Wald test in non-inferiority clinical trials, which 
is used for studies with a primary endpoint based on SDH. Simulations and an example 
showed that the presented sample size formula can correctly estimate the required 
sample size. The presented formula is most applicable when SDH is employed to reveal 
the close to “real world” relationship between the treatment and endpoints when 
competing risks are present, whereas the sample size formula for CSH may be used 
when the objective is the theoretical relationship. In many cases, apart from biological 
studies, learning the experimental treatment’s comprehensive effects on all events may 
be more beneficial and attractive for an intuitive explanation (Parpia et al., 2013), and 
all the patients are treated in the real world where multiple events may occur. Thus, we 
recommend using the SDH as the primary endpoint in clinical trials when appropriate, 
with the presented formula to better estimate the sample size.  
According to the guideline from FDA (U.S. Food and Drug Administration) for 
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non-inferiority trials, the estimated treatment effect from the historical trials should be 
used to derive the non-inferiority margin for a non-inferiority trial. However, if the SDH 
model was not used in related studies, we suggest that the non-inferiority margin for 
SDH be calculated from the CSH by Lau’s formula (Lau, 2009). If neither SDH nor 
CSH is available, a pilot study might be more appropriate.  
If 0 1   and 1 1  , the presented formula can be used for superiority testing. 
The body of the presented formulas and the formula of Latouche (2004) look the same. 
Nevertheless, the presented formula here is derived based on the Weibull distribution, 
where Latouche’s formula is based on the exponential distribution. In addition, the 
calculation of parameter   in Latouche’s formula is different from that of w  in the 
denominator of the formula presented here. 
One potential criticism of the competing risks application is that multiple events 
can be reasonably combined into a composite endpoint. For example, CD and NCD can 
be combined into overall survival if the detailed causes of death are not of interest and if 
the CD rate affected by NCD is not of concern. Nevertheless, not all events can be 
combined into a composite endpoint. For example, when the events defined are 
opposites, such as recovery vs. death for hospitalized patients with SARS (Chen, 2009), 
they cannot be combined into a composite endpoint. In practice, a competing risks 
model can reveal the underlying relationships among the studied events and variables, 
whereas a composite-endpoint method can simplify the analysis strategy without 
missing too much important information. More details are provided in recently 
published papers (Mell, 2010; Rauch, 2013). 
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The percentage of the event of interest of all of the events at the end of the 
follow-up interval, i.e., 1xq , was assumed to be constant in this paper. Nevertheless, the 
percentage can be treated as a function of the maximum follow-up time of each 
individual. The maximum follow-up time of each individual is not fixed because a 
random enrollment time exists. Therefore, the variable 1xq  in terms of the follow-up 
time can be adopted in Formula (6) to cover more general situations. 
In this paper, the uniform accrual time was employed, i.e., the number of subjects 
enrolled by a Poisson distribution. In addition, the accrual rate was constant over the 
interval [0, R]. In reality, this accrual rate can be increasing or decreasing over time or 
can follow a non-monotone pattern. A constant rate was assumed to simplify the 
equations; however, other distributions have been discussed by various researchers 
(Maki, 2006; Crisp, 2008). For instance, other distributions can be used by 
incorporating the density function into Equation (6) and by replacing 1/ R . 
 
 
Appendix 
A: Proof of the sample size formula in NiCTCR. 
The hypothesis is as follows: 
 0 0 1 0: ln : lnH b H b    , 
where exp( )b  is the SDH ratio   and 0 ( 0exp( )b ) is the non-inferiority margin of 
the SDH ratio. 1 ( 1exp( )b ) denotes the SDH ratio under the alternative hypothesis. 
The independent variable x is an indicator of groups. The x = 0 represents the control 
group and x = 1 represents the experimental group. The risk set at time t can be written 
as follows: 
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   ( ) { : 1 , , }1 ,SD i i iRS t i t T t T d i N       ,  
iT  denotes the time to any event of the ith subject and D denotes the event code which 
is the event of interest (D = 1), competing event (D = 2) and censoring (D = 0). The id  
is the event code of the ith subject. The log partial likelihood can be expressed as 
follows: 
1 ( )
ln ( ) { 1} ln( exp( ))
SD
i
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i i j
i j RS T
L b I d bx bx
 
        . 
According to the Fine-Gray’s paper (1999), the score statistic is expressed as 
follows: 
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The information can be derived by the following formula: 
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and xiY  denotes the number of patients at risk of group x at iT , i.e. the number of 
subjects within ( )SD iRS T . Consequently, the following formula can be obtained, 
 
0 1
2
1 0 1
exp( )( ) { 1}
exp( )
i i
n
i i i
N
i
Y Y bI b I d
Y Y b
   . (A.3) 
Let xF  and xf  be the cumulative incidence function and sub-density function of 
the event of interest in group x and xF  be the cumulative incidence function of 
censoring. N denotes the total number of subjects required in the two groups. xp  
denotes the assignment proportion of subjects to group x. Therefore, xiY  can be 
rewritten as follows:  
(1 ( ))(1 ( ))xi x x i x iY Np F T F T   . 
Given that 
1
0
( ) ( )(1 ( ))xx
x
xU t p f t F t

  , the Equation (A.3) can be rewritten as 
follows: 
1
0
0 2
0
1
[ (1 ( ))(1 ( ))]exp( )
( ) ( )
{ [ (1 ( ))(1 ( ))]exp( )}
f
x x xT x
n
x
x x x
Np F t F t bx
I b U t dt
Np F t F t bx


 

 
 , 
If 1
0
(1 ( ))(1 ( ))( )
[ (1 ( ))(1 ( ))]exp( )x
x x x
x
x
x
x
Np F t F tt
Np F t F t bx


 
  , then  
0 10
( ) ( ) ( ) ( )f
T
nI b t t U t dt   . 
In practice, 1 0( ) ( )F t F t  is most common. In such a situation and under the 
alternative hypothesis, the following formula can be noted as follows: 
0 1 exp( )
( | ) xx
pt b
p p b
   . 
Therefore, the variance is expressed as follows: 
17 
 
10 1
2
0 1
( ) ( )
e( xp( ))
p pV b w
p p b
   (A.4), 
where 
0
( )f
T
w U t dt  . 
The true coefficient is assumed to be known in the planning stage, hence the 1b  
under 1H  is employed in the variance calculation. Therefore, the Wald test statistic is 
expressed as follows: 
0 1( ) ~ Gussian(0, ( ))VW N b bb  . 
The sample size formula can be derived as follows: 
0
/2 1 1 1
1
0 0 1 0 1
/2 1 1 1
0 1
/2
ˆ[ ln( )]1 ( | : ln( ) 0)
ˆ[ ln( ) ln( ) ln( )] [ ln( ) ln( )]( | : ln( ) 0)
[ ln( ) ln( )](
( )
(0) (0)
       .
(0)
)
N bP Z H b
V b
N b NP Z H b
V V
NZ
V



       
             
   
 
After considering the inverse normal distribution function for two sides of the equation, 
we can obtain the following formula: 
0 1
1 /2
[ ln( ln ]
( )
() )
0
Z Z
V
N
 
    . 
The total number of subjects can be calculated from the following formula: 
2 2
1 /2 /2
0 1
0 1 0
1
1
( )
ln( l
(0)
) n( ln( ln() ) )
Z Z Z Z
N V p p w    
            

 

 
 . 
Under the assumption that 1 0( ) ( )F t F t  and 1 0( ) ( )F t F t , the ( )U t  can be 
expressed as 0 0(t) 2 ( )(1 ( )U f t F t  . The sub-density function ( )xf t  can be expressed 
as 1 111 1 1 1exp( )
k k
x x xq k t t    (Beyersmann, 2011; Pintilie, 2006) with the Weibull 
survival time assumption. In this assumption, xDq  denotes the probability that an 
individual who has experienced an event, undergoes the event of interest. Dk  denotes 
18 
 
the shape parameter of the event D, which is identical across two groups. xD  indicates 
the scale parameter of the event D of group x. Let   denote the hazard rate of 
censoring distribution. If no accrual interval exists, 
1
0
x
x
w w

   is expressed as follows: 
1 11
1 1 1 1
0
exp( ) exp( )
f
k k
T
x x x xw q k u u u du    . 
The same terminology found in reference (Rubinstein, 1981) required in the 
presence of different enrollment times considering the prolongation of the follow-up 
period. The incidence rate can be calculated as follows: 
1 111
1 1 10
exp( ) exp( )f
f
T R k kx
x x xT
tqw k u u u dudt
R
       , 
where fT  and R indicate the follow up and enrollment intervals, respectively. 
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Table 1. The parameter combination settings for sample size for NiCTCR 
Parameter Values 
01q  0.3, 0.5, 0.8 
1 2( , )k k  (0.5, 0.5), (1, 1), (2, 2), (0.5, 1.5), (1.5, 0.5) 
01  1, 2 
2  0.15, 0.5 
  0, 0.1 
( 0 1,  ) (1.3, 1.0) 
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Table 2. The sample size required for different parameter combinations for NiCTCRa 
1k  1  2  0    Eventsb NCRc NSEd 
0.5 0.225 0.047 1.50 0 220 538 396 
    0.02 220 576 424 
1 0.073 0.021 1.50 0 220 486 358 
    0.02 220 544 400 
2 0.008 0.004 1.50 0 220 410 306 
    0.02 220 478 358 
a. 1 1  , 7.5fT  , 12R  , 0.05  , 01 0.737q  , power=0.85 
b. Events required in two groups 
c. Total sample size required by the presented formula 
d. Total sample size calculated by formulas for the non-inferiority study with 
time-to-single-event (Crisp, 2008; Chow, 2008) 
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Figure 1. The power and censoring rate of the sample size formula for NiCTCR 
 
 
 
